You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The program received an IDE from the FDA this summer and plans to release its first batch of genetic data to the research community late next year.
The study, which focused on Europeans, also highlighted a role for enhancers during embryonic development in determining facial features.
Patients who underwent SLCO1B1 testing were able to lower their cholesterol levels similarly to those who did not, indicating that testing does not cause harm.
At ASHG, a FinnGen researcher reported new recessive disease associations for cataracts, hearing loss, and other conditions, identified through the population study.
Since the mutations are only found in a subset of patients' blood cells, the disorder, called VEXAS, might be treatable with a bone marrow transplant.
Under the deal, the companies will offer NRGene software for SNP set creation with AgriPlex's genotyping platform and data analysis software.
The integration on the Microsoft Azure cloud is helping Kaiser make its vast genomics dataset available to a wider pool of researchers.
In PLOS this week: chromosomal integration of human herpesvirus 6, gene expression predictions across populations, and more.
In PLOS this week: genetic analysis of malaria parasite populations in Southeast Asia, genomic surveillance of yellow fever virus in São Paulo, and more.
A composite polygenic risk score helped cluster individuals by lifespan, though it appeared to be most informative for younger individuals.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.